Shares of NeOnc Technologies Holdings surged 15.1% to $3.44 after the company disclosed that its two top executives spent $629,000 of their own money buying stock on the open market — a vote of personal confidence that investors are now pricing in. The purchases follow a critical clinical milestone, but the road ahead remains steep and expensive.
The CEO Is Buying Below the Price Institutions Just Paid
CEO Amir Heshmatpour has purchased 111,000 shares for roughly $418,700 at an average cost of about $3.77 per share since August 12.
Chief Scientific Officer Thomas Chen bought 49,016 shares for approximately $210,000. Notably, NeOnc just announced a $15 million registered direct offering at $4.20 per share, meaning Heshmatpour's latest purchase occurred at a substantial discount to that financing price. When insiders buy below what institutions agreed to pay, it suggests management believes the stock is undervalued — or at least wants investors to think so. Heshmatpour says his personal investment in NeOnc shares now exceeds $1.5 million over the past year.
The Clinical Data Beat Expectations, but the Study Was Small
The Phase 2a study met its primary endpoint: 48.9% of patients showed no cancer progression at six months, compared with a 20% benchmark for standard care (p = 0.0047).
Median overall survival hit 26.09 months with no major toxicities. Those numbers look impressive — current salvage therapies for recurrent brain cancer typically yield just six to nine months of survival. But caution is warranted: the study did not reach planned enrollment, was not powered as a confirmatory trial, and had no randomized control arm.
Only 24 patients were enrolled.
Fresh Cash Buys Runway, but Dilution Is the Trade-Off
The $15 million offering includes 3.57 million shares plus warrants for another 3.57 million shares at $4.20. That's meaningful dilution for a micro-cap stock. However, NeOnc just redeemed all 6,000 shares of Series A Convertible Preferred Stock for $6 million in cash, with zero common shares issued — removing an overhang that could have diluted shareholders further at a deep discount.
The Real Test Is the FDA Meeting That Hasn't Happened Yet
NeOnc intends to request a Type B meeting with the FDA to discuss a potential path toward a registration-level study — the kind of larger, rigorous trial required for drug approval. The company remains clinical-stage, with substantial risks around additional trials, financing, and commercialization, and Phase 2a results do not guarantee FDA approval. Until the FDA signals willingness to accept an accelerated path, the insider buying is a confidence statement, not a guarantee.